About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Value of Screening MRI Brain in Stage IV Non-small Cell Lung Cancer

NCT05864794·3 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

F. Bensch, MD, PhD
CONTACT
0031503616161 f.bensch@umcg.nl
L.B.M. Hijmering, MD
CONTACT
0031503616161 l.b.m.hijmering-kappelle@umcg.nl

Lead

University Medical Center Groningen

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Histologically or cytologically confirmed stage IV metastatic NSCLC, not amenable to curative treatment.
Fit for systemic treatment (PS 0-2) according to standard of care.
No symptoms of brain disease disease assessed according to standard clinical care by the thoracic oncologist.

You may not be if

Prior/concomitant therapy for stage IV disease.
Oncogenic diver mutation (e.g. EGFR, ALK, ROS1, RET, MET, and BRAF) with approved targeted treatment.
Contraindications for MRI scan with contrast as per standard of care protocol of the institution.

The record

StatusRecruiting

PhaseNo phase

Taking part100

StartedMay 2024

UpdatedJun 9, 2026

Conditions

Non Small Cell Lung Cancer Metastatic

Where3

University Medical Center Groningen
Groningen, Provincie Groningen, Netherlands
Maastricht UMC+
Maastricht, Netherlands
Ommelander Ziekenhuisgroep
Scheemda, Netherlands

Clareo Health | Value of Screening MRI Brain in Stage IV Non-small Cell Lung Cancer